Virulence Profiles of Bacteremic Extended-Spectrum β-Lactamase-Producing *Escherichia coli*: Association with Epidemiological and Clinical Features

Jesús Rodríguez-Baño1,2,*, Jesús Mingorance3, Natalia Fernández-Romero3, Lara Serrano1, Lorena López-Cerero1, Alvaro Pascual1,4, the ESBL-REIPI group*

1 Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Sevilla, Spain, 2 Servicio de Microbiología, Hospital Universitario La Paz - IDiPAZ, Madrid, Spain, 3 Departamento de Medicina, Universidad de Sevilla, Sevilla, Spain, 4 Departamento de Microbiología, Universidad de Sevilla, Sevilla, Spain

Abstract

There is scarce data about the importance of phylogroups and virulence factors (VF) in bloodstream infections (BSI) caused by extended-spectrum β-lactamase-producing *Escherichia coli* (ESBLEC). A prospective multicenter Spanish cohort including 191 cases of BSI due to ESBLEC was studied. Phylogroups and 25 VF genes were investigated by PCR. ESBLEC were classified into clusters according to their virulence profiles. The association of phylogroups, VF, and clusters with epidemiological features were studied using multivariate analysis. Overall, 57.6%, 26.7%, and 15.7% of isolates belonged to A/B1, D and B2 phylogroups, respectively. By multivariate analysis (adjusted OR [95% CI]), virulence cluster C2 was independently associated with urinary tract source (5.05 [0.96–25.48]); cluster C4 with sources other than urinary of biliary tract (2.89 [1.05–7.93]), and cluster C5 with BSI in non-predisposed patients (2.80 [0.99–7.93]). Isolates producing CTX-M-9 group ESBLs and from phylogroup D predominated among cluster C2 and C5, while CTX-M-1 group of ESBL and phylogroup B2 predominantes among C4 isolates. These results suggest that host factors and previous antimicrobial use were more important than phylogroup or specific VF in the occurrence of BSI due to ESBLEC. However, some associations between virulence clusters and some specific epidemiological features were found.

Introduction

Most extraintestinal infections due to *Escherichia coli* are caused by isolates derived from the so-called virulent phylogenetic groups (PG) B2 and D, which exhibit more virulence factors (VF) than other PGs such as A and B1, hence considered “low virulence” or “commensal” PGs [1,2]. Specifically, in studies on bloodstream infections (BSI) caused by *E. coli*, >70% of the isolates belonged to PGs B2 (which was predominant) and D [3–8]. Isolates from PG B2 have been associated with BSI with a urinary tract source [4,5,7] and in non-predisposed patients [7,9], while PG A has been found with increased frequency in nosocomial BSI, compromised hosts [4,6,10] and in BSI caused by antibiotic-resistant isolates [5,6,8].

Some VFs have been assigned a pathogenic role in extraintestinal infections based on comparisons with rectal isolates, association with infections in non-predisposed patients, and animal models [11]. In studies dealing with BSI, several VF has been found to be associated with specific epidemiologic features, but it is *padGII* that has been more consistently associated with urinary tract sepsis as opposed to other sources, and in patients without predisposing factors [4,9,12].

Extended-spectrum beta-lactamase-producing *Escherichia coli* (ESBLEC) are increasing worldwide as a cause of community and nosocomial BSI, frequently affecting patients with predisposing conditions [12,13]. There are scarce data about the distribution of PGs and VF in BSI due to ESBLEC [14] and their association with antimicrobial resistance. Also, to the best of our knowledge, the impact of specific VF in the epidemiology of BSI due to ESBLEC has not been studied. Finally, there is some controversy about the real virulence of ESBLEC, including isolates producing CTX-M-15 belonging to the worldwide spread clone ST131 [16–18].

The objectives of this study were to investigate the PGs and prevalence of VF genes in a well characterized collection of ESBLEC causing BSI, and whether some PGs and VF (individ-
ually or in clusters) were associated with the epidemiology, patients' features and source of BSI.

**Methods**

**Study Design and Patients**

Data and isolates from a prospective cohort including 191 cases of BSI due to ESBL-E. coli from 13 Spanish hospitals were used for this analysis. The epidemiology, clinical features, outcomes, types of ESBL and susceptibility data of this cohort were previously reported [13,14]. Briefly, all monomicrobial BSI in patients with signs or symptoms of systemic infection caused by ESBL-E. coli diagnosed in the participating hospitals between October 2004 and January 2006 were included. The cases were detected by daily review of microbiological results of blood cultures at each center. Data collected included demographics, acquisition classified as community, healthcare-associated or nosocomial [13], chronic underlying diseases, severity of underlying condition according to Charlson index [19], invasive procedures, exposure to antibiotics in the preceding 2 months, and source of BSI according to clinical and microbiological criteria.

For this analysis, patients with any of the following were considered to have systemic predisposing features for BSI: diabetes mellitus, liver cirrhosis, chronic renal insufficiency, immunosuppressive therapy, and neutropenia. Patients with a procedure-associated BSI (including vascular catheter, urinary catheter, endoscopic procedures and surgery), or any urinary or biliary tract BSI in the presence of obstructive diseases of these tracts were considered to have local predisposing factors for BSI. The study was approved by the Ethics Committee of Hospital Universitario Virgen Macarena which waived the need to obtain consent because all data were analysed anonymously and the observational nature of the study.

**Microbiological Studies**

Methods for bacterial identification, susceptibility studies and ESBL confirmation and characterization were previously reported [13,14]. Briefly, ESBL production and susceptibility by microdilution to cefuroxime, cefotaxime, cefazidime, cefepime, gentamicin, tobramycin, amikacin, imipenem, meropenem, trimethoprim-sulfamethoxazol, ciprofloxacin, fosfomycin, and ticaglycine were studied according to CLSI recommendations [20]; a resistance score (number of antimicrobials to which the isolate was resistant) was calculated for each isolate. β-lactamase characterization was carried out by isoelectric focusing, PCR of the bla genes, and sequencing. ST131 clone was studied by O25b typing [17] and analysis for allele 3 of pabB [21]; the phylogenetic group was determined by multiplex PCR [22].

Twenty-five genes codifying for putative VF were studied, including adhesins (papC, papGII, papGI, fimH, sfaD/E, afaB/C, iha); toxins (cnf1, cdtB, hlyA); related to iron acquisition (iuC, iroN, iucD, ireA, and fyuA); protectins (kps MTII, traT, cwaC, and ompT); and miscellaneous (iha, maIX, og, and usp). The presence/absence of VF genes was studied by PCR using previously described primers [2,23–31]. Total DNA was purified from each strain with the UltraClean Microbial DNA purification kit (MO BIO Laboratories Inc., Carlsbad, CA). DNAs were distributed in 96-well master plates and PCRs were done in 50 μL mixtures containing 5 μl (20 ng) template DNA, 0.2 μM of each primer, 0.2 μM mix dNTPs and 1U DNA polymerase (Biotools S. L., Spain) in 1X buffer with MgCl2. PCR conditions were as follows: 5 min at 95°C, followed by 30 cycles of 30 s at 95°C, 30 s at annealing temperature of each primer pair, 1 min at 72°C, and a final 5 min incubation at 72°C. The PCR products were analyzed by electrophoresis in 96-well agarose gels (VG-FAST, Fisher Bioblock Scientific) stained with GelRed™ (Biotium Inc.). A virulence score (number of VF genes) was calculated for each isolate. The similarity of the isolates according to their VF genotypes was studied by constructing a dendogram using the binary patters (0, 1) of VF for each isolate; clusters of isolates were identified using the Dice similarity coefficient. After reviewing the data obtained, a 70% similarity threshold was used after reviewing the database (a 60% threshold was not discriminative enough, since only one cluster included 72.2% isolates; and a 80% threshold found only 4 clusters with >5 cases including 32.4% of the isolates).

**Statistical Analysis**

Percentages were compared using the chi squared test or the Fisher exact test, as appropriate, and continuous variables using the Mann-Whitney U test. Multivariate analysis were performed by logistic regression; variables with a univariate p value <0.1 were introduced in the models, and selected using a stepwise backward process; 0.1 was set as the limit for removal of terms. All tests were performed using SPSS 18.0.

**Results**

Among the 191 ESBL-E. coli bacteremic isolates, 55 (28.8%) belong to PG A, 53 (28.8%) to PG B1, 51 (27.7%) belong to PG D, and 30 (15.7%) to B2. The median (IQR) virulence score were 10 (9–12) for B2, 8 (7–9) for D, 5 (4–6) for B1, and 4 (2–6) for A. Among the B2 isolates, 21 (70% of B2, 10.9% of the whole series) were O25b and pabB3 positive and were considered as belonging to ST131. For easier understanding, PGs A and B1 were analyzed together because both showed similar virulence scores, frequency of VF (only fimH, iucD, and iroN were significantly more frequent among B1 than among A), ESBLs (predominance of CTX-M-14), and resistance patterns.

The frequency of VF genes according to PG is shown in table 1. In summary, papC, afaB/C, iha, fimH, sat, fyuA, iutA, kps MTII, ompT, iueA, usp, and maIX were more frequent among B2 and D than in A/B1; additionally, papGII, hlyA, cnf1, and cdtB, although infrequent, were more prevalent in B2 than in A/B1; and papGII and iroN were more frequent in D than in A/B1. Finally, sfaD/E, afaB/C, sat, fyuA, kps MTII, ompT, usp, and maIX were more frequent in B2 than in D, while only papGII was more frequent in D than in B2.

 Among the B2 isolates, 21 (70%) were ST131. The ESBLs produced by ST131 and non-ST131 B2 isolates differed; thus, CTX-M-15 was produced by 5/21 of ST131 isolates (71.4%) and by 0/9 of non-ST131 B2 isolates (p = 0.0007), while the numbers for CTX-M-14 were 2/21 of ST131 and 5/9 of non-ST131 B2 isolates (9.5% vs. 55.5%, p = 0.01). In comparison with non-ST131 B2 isolates, ST131 harboured more frequently afaA/B (42.9% vs. 0, p = 0.02), iha (66.7% vs. 22.2%, p = 0.04), and sat...
Table 1. Virulence factor genes, ESBL groups and antimicrobial resistance of 191 ESBL-producing *E. coli* isolates causing BSI according to phylogroups.

|                      | All isolates (n = 191) | Phylogroup B2 (n = 30) | Phylogroup D (n = 51) | Phylogroups A/B1 (n = 110) |
|----------------------|------------------------|------------------------|-----------------------|----------------------------|
| Virulence score, median (IQR) | 6 (4–8)                | 9 (8–13)               | 7 (6–9)               | 6 (2–7)                    |
| **VF**               |                        |                        |                       |                            |
| *papC*               | 45 (24)                | 8 (27)                 | 23 (45)               | 14 (13)                    |
| *papGI*              | 0                      | 0                      | 0                     | 0                          |
| *papGIII*            | 31 (16)                | 3 (10)                 | 20 (39)               | 8 (7)                      |
| **aflA/B/C**         | 7 (4)                  | 4 (13)                 | 1 (2)                 | 2 (2)                      |
| *iha*                | 30 (16)                | 16 (53)                | 10 (20)               | 4 (4)                      |
| *tempH*              | 160 (84)               | 28 (93)                | 48 (94)               | 84 (76)                    |
| *hlyA*               | 4 (2)                  | 3 (10)                 | 1 (2)                 | 0                          |
| *cnfI*               | 4 (2)                  | 3 (10)                 | 1 (2)                 | 0                          |
| *cdgB*               | 4 (2)                  | 3 (10)                 | 1 (2)                 | 0                          |
| *sat*                | 39 (20)                | 19 (63)                | 17 (33)               | 2 (3)                      |
| *fyuA*               | 98 (51)                | 28 (93)                | 37 (73)               | 33 (30)                    |
| *sacA*               | 157 (82)               | 28 (93)                | 46 (90)               | 83 (76)                    |
| *sacD*               | 140 (73)               | 23 (77)                | 41 (80)               | 76 (69)                    |
| *iroN*               | 118 (62)               | 17 (57)                | 29 (57)               | 72 (66)                    |
| *kpS MIR*            | 44 (23)                | 20 (67)                | 19 (37)               | 5 (5)                      |
| *traT*               | 141 (74)               | 28 (83)                | 37 (72)               | 79 (72)                    |
| *cvaC*               | 66 (35)                | 7 (23)                 | 16 (31)               | 43 (39)                    |
| *ompT*               | 102 (53)               | 27 (90)                | 32 (63)               | 43 (39)                    |
| *iheA*               | 15 (8)                 | 7 (23)                 | 7 (14)                | 1 (1)                      |
| *usp*                | 33 (17)                | 26 (87)                | 7 (14)                | 3 (3)                      |
| *molX*               | 75 (39)                | 28 (93)                | 34 (67)               | 13 (12)                    |
| *svg*                | 3 (2)                  | 2 (7)                  | 0                     | 1 (1)                      |
| *ireA*               | 29 (15)                | 3 (10)                 | 19 (37)               | 7 (6)                      |
| ESBL group [d]       |                        |                        |                       |                            |
| CTX-M-9 group [a]    | 122 (64)               | 10 (33)                | 41 (80)               | 71 (65)                    |
| CTX-M-1 group [b]    | 42 (22)                | 17 (57)                | 8 (16)                | 17 (16)                    |
| SHV group [c]        | 33 (17)                | 4 (13)                 | 5 (10)                | 24 (22)                    |
| TEM group [d]        | 1 (1)                  | 0                      | 0                     | 1 (1)                      |
| Resistance to        |                        |                        |                       |                            |
| Cefotaxime           | 184 (96)               | 28 (93)                | 50 (98)               | 106 (96)                   |
| Ceftazidime          | 70 (37)                | 14 (47)                | 12 (24)               | 44 (40)                    |
| Cefepime             | 124 (65)               | 19 (63)                | 35 (69)               | 70 (64)                    |
| Amoxicillin/clavulamic acid | 73 (38)             | 19 (63)                | 20 (39)               | 34 (31)                    |
| Piperacillin/tazobactam | 16 (8)               | 5 (17)                 | 3 (6)                 | 8 (7)                      |
| Ciprofloxacin        | 129 (68)               | 18 (60)                | 36 (71)               | 75 (68)                    |
| Gentamicyn           | 39 (20)                | 4 (13)                 | 14 (28)               | 21 (19)                    |
| Tobramycin           | 34 (18)                | 13 (43)                | 10 (20)               | 11 (10)                    |
| Amikacin             | 3 (2)                  | 2 (77)                 | 1 (2)                 | 0                          |
| Co-trimoxazole       | 115 (60)               | 19 (63)                | 38 (75)               | 58 (53)                    |
| Resistance score, median (IQR) | 5 (4–7)              | 6 (4–7)                | 5 (4–6)               | 5 (4–5)                     |

[a] Higher in B2 vs A/B1 (p < 0.05).
[b] Higher in B2 vs D (p < 0.05).
[c] Higher in D vs B2 (p < 0.05).
[d] Higher in D vs A/B1 (p < 0.05).
[e] Higher in A/B1 vs D (p < 0.05).
All other comparisons, p > 0.05.
The opposite occurred with systemic (0 vs. 33.3, p = 0.02) and ind (0 vs. 33.3, p = 0.02).

The features of the patients according to PG are shown in Table 2. Isolates from PG B2 and D did not seem to be related to lower frequency of predisposing features for invasive infections than isolates from PG A/B1. The only significant difference was cancer, which was less frequent among patients with B2 isolates than among those with A/B1. Also, there were no significant differences in the epidemiological features or sources of BSI. Even when B2 and D isolates were grouped, the only significant difference with A/B1 isolates was that the former more frequently occurred in nursing home residents (9/81 [11.1%] vs 3/110 [2.7%], p = 0.03).

The association of all 25 specific VF genes studied with predisposing factors for BSI, type of acquisition, previous antibiotic use, or source of BSI was studied. Overall, no association was found (data not shown) with 2 exceptions: papGII was more frequent in patients without any predisposing factor (local or systemic) than in patients with them (25% vs 12%, p = 0.02), while the opposite occurred with sat (25% vs 40%, p = 0.03). We also performed stratified analysis according to source. Among patients with a urinary tract source of BSI, those without any local or systemic predisposing feature had isolates with a higher prevalence of papC and papGII than those with any predisposing factor (46% vs 10%; p = 0.01, and 36% vs 7%; p = 0.001, respectively). No significant associations were found between VF and other sources of BSI.

The profiles of VF genes were extremely diverse: the 191 strains showed 159 different profiles, of these 134 were unique, 21 profiles appeared twice, 2 appeared three times, and one profile was repeated four times and another one appeared five times. Such diversity prompted us to classify them in clusters; 29 clusters were found using a 70% similarity threshold; 6 clusters arbitrarily named C1–C6 grouped 128 isolates (67%). PGs, ESBLs, antimicrobial resistance, and epidemiological data according to cluster are shown in Table 3; distribution of VF among the clusters are shown in Figure 1. In summary, isolates from C1 caused infections in younger patients; those in C2 were associated with higher frequency of urinary tract source; C4 isolates showed higher frequency of CTX-M-1 group of ESBLs, resistance to amoxicillin/clavulanic acid and tobramycin, and bacteremia from sources other than urinary or biliary tracts; those in C5 had the lower frequency of local predisposing factors; and C6 isolates showed less frequent resistance for ciprofloxacin. Sixteen of the 22 isolates from C4 (73%) belonged to ST131; also, 76% isolates from ST131 belonged to C4.

To further investigate the association of C2 with urinary tract source, multivariate analysis were performed. We introduced the following variables: age, gender, acquisition, local predisposing factor, systemic predisposing factor, PG, cluster, papGII, VF score, ESBLs, and antimicrobial resistance score. C2 was independently associated with urinary tract source after controlling for age, local and systemic predisposing factors, while PGs, papGII, VF score or antimicrobial resistance were not (Table 4). We did the same to investigate the association of C4 with sources other than urinary or biliary tracts. C4 was independently associated, while again PGs, specific VF, VF score, and antimicrobial resistance score were not.

Finally, we analyzed the association between different microbiological features and absence of predisposing systemic and local features for BSI. In the univariate analysis, cluster 5, papC, papGII, sat, female gender, lower age, community, source, and no receipt of previous antimicrobial use showed a p value <0.1 and were introduced in the multivariate analysis. The variables selected as independent predictors of BSI in non-predisposed patients were lower age, community-acquired BSI, no receipt of previous antimicrobials, and cluster 5 (Table 5).

**Discussion**

Our study showed that the phylogenetic background or virulence profiles of ESBLEC causing BSI in Spain were different to what would be expected for bacteremic *E. coli*. The fact that isolates from the so-called “low virulent” PGs A and B1 predominated as caused of BSI is in contrast with previous studies including mainly non-ESBL-producing isolates, in which B2 ad D were predominant [3–8]. As a consequence, the prevalence of all VF studied was much lower among ESBLEC isolates than among previous collections of blood isolates of *E. coli* except for *intA*, *inaN*, *traT*, and *cvaC* [2–4,6,7,12]. There are, to our knowledge, scarce previous data on collections of blood ESBLEC isolates. In a study from The Netherlands including 41 ESBLEC blood isolates, only 22% of isolates belong to A or B1 PGs [15]. Similar to our results, PG A was predominant in the subgroup of ESBL-producers from a French study; however, only 19 ESBLEC were included [8].

Three facts may explain our results. First, most cases occurred in patients with local or systemic predisposing factors for BSI; hence, less virulence factors would be required to cause invasive infection in such patients. Second, previous antibiotic treatment was common, which would have selected for ESBLEC because of their multidrug-resistant nature regardless their virulence profile. Although antimicrobial resistance has been frequently shown to be more frequent among isolates from the A and B1 PGs than among B2 isolates [11], B2 isolates were more frequently resistant to several antimicrobials (particularly amoxicillin-clavulanic acid and tobramycin) than isolates from other PGs. This reflects the resistance profile of isolates of ST131 producing CTX-M-15 [32,33], which comprised most B2 isolates in our series. And third, in a recent study performed in France, non-ST131 B2 *E. coli* isolates were found to rarely produce CTX-M enzymes [34]; this, together with the fact that ST131 was not predominant in our series, would provide an additional explanation for the low rate of B2 isolates.

Even though ESBLEC from the B2 and D PGs showed, as expected, a much higher content in VF, we did not find B2 and D isolates to have caused infections in clearly less predisposed patients than A/B1 isolates, with the exception of cancer (less frequent among B2). A recent study on non-ESBL-producing *E.
coli found that B2 isolates were predominant as cause of bacteremia and spontaneous peritonitis in patients with liver cirrhosis [35]; of note, liver cirrhosis was more frequent among patient with B2 isolates than those with D or A/B1 isolates in our series, but the differences did not reach statistical significance. Also, we found that PGs or specific VFs were not independently associated to source of BSI. In previous studies of E. coli bacteremic isolates, those from PG B2 had been associated with urinary tract source of BSI [4,5,7]. As regards specific VF, several studies have investigated their association with BSI sources; the studies were different in populations, definitions, and VF studied, making it difficult to draw clear conclusions [4,9,12]. However, papGII has been more consistently associated with urinary tract source in these studies. We did not find such association, although papGII was more frequent in crude analysis among non-predisposed patients with urinary tract BSI.

Overall, these results suggest that host factors and previous antimicrobial use were more important than phylogroup background, virulence score or specific VF in the occurrence of BSI due to ESBLEC. However, by investigating the existence of clusters of isolates according to their VF content, we found some associations between virulence background and some specific epidemiological features. Thus, cluster C2 (mainly PG D, CTX-M-14 producers) was independently associated with urinary tract source.

### Table 2. Comparison of predisposing features according to phylogroup among 191 patients with bacteremia due to ESBL-producing E. coli.

|                        | All isolates (n = 191) | Phylogroup B2 (n = 30) | Phylogroup D (n = 51) | Phylogroups A/B1 (n = 110) |
|------------------------|------------------------|------------------------|-----------------------|---------------------------|
| Age in years, median (IQR) | 71 (55–78)            | 72 (58–82)             | 71 (58–78)            | 69 (54–77)                |
| Male gender            | 107 (56)               | 20 (66.7)              | 28 (54.9)             | 59 (53.6)                 |
| Acquisition            |                        |                        |                       |                           |
| Community              | 23 (12)                | 4 (13.3)               | 3 (5.9)               | 16 (14.5)                 |
| Healthcare-associated  | 72 (37.6)              | 12 (40)                | 24 (47.0)             | 36 (32.7)                 |
| Nosocomial             | 96 (50.2)              | 14 (46.7)              | 24 (47.9)             | 58 (52.7)                 |
| Nursing home resident  | 12 (6.2)               | 2 (6.7)                | 7 (13.7)              | 3 (2.7)                   |
| Charlson index, median (IQR) | 2 (1–4)              | 2.5 (1–4)             | 2 (1–5)               | 2 (1–4)                   |
| Diabetes mellitus      | 52 (27.2)              | 9 (30)                 | 12 (23.5)             | 31 (28.2)                 |
| Chronic pulmonary disease | 34 (17.8)             | 4 (13.3)               | 9 (17.6)              | 21 (19.1)                 |
| Cancer                 | 55 (28.7)              | 4 (13.3)<sup>a</sup>  | 15 (29.4)             | 36 (32.7)                 |
| Liver cirrhosis        | 18 (9.4)               | 5 (16.7)               | 4 (7.8)               | 9 (8.2)                   |
| Chronic renal insufficiency | 28 (14.6)            | 3 (10)                 | 5 (9.8)               | 20 (18.2)                 |
| Immunosuppressive therapy | 27 (14.1)             | 4 (13.3)               | 9 (17.6)              | 14 (12.7)                 |
| Obstructive urinary disease | 43 (22.5)            | 7 (23.3)               | 7 (13.7)<sup>c</sup> | 29 (26.4)                 |
| Biliary tract disease  | 18 (9.4)               | 2 (6.7)                | 3 (5.9)               | 13 (11.8)                 |
| Neutropenia            | 10 (5.2)               | 1 (3.3)                | 3 (5.9)               | 6 (5.5)                   |
| Urinary catheter       | 66 (34.5)              | 13 (43.3)              | 17 (33.3)             | 36 (32.7)                 |
| Central venous catheter | 53 (27.7)             | 5 (16.7)               | 12 (23.5)             | 36 (32.7)                 |
| Mechanical ventilation | 8 (4.1)                | 1 (3.3)                | 3 (5.9)               | 4 (3.6)                   |
| Previous surgery       | 44 (20.9)              | 6 (20)                 | 14 (27.5)             | 24 (21.8)                 |
| Predisposing factor, local | 122 (63.8)            | 19 (63.3)              | 30 (58.8)             | 73 (66.4)                 |
| Predisposing factor, systemic | 100 (52.3)         | 16 (53.3)              | 24 (47.1)             | 60 (54.5)                 |
| Predisposing factors, systemic or local | 158 (82.7)     | 24 (80)                | 41 (80.4)             | 93 (84.5)                 |
| Previous antibiotic use, any | 107 (56)             | 18 (60)                | 28 (54.9)             | 61 (55.5)                 |
| Fluoroquinolones       | 49 (25.6)              | 7 (23.3)               | 12 (23.5)             | 30 (27.3)                 |
| Cephalosporins         | 53 (27.7)              | 9 (30)                 | 15 (29.4)             | 29 (26.4)                 |
| Amoxicillin/clavulanic acid | 20 (10.4)             | 3 (10)                 | 3 (5.9)               | 14 (12.7)                 |
| Source                 |                        |                        |                       |                           |
| Urinary tract          | 90 (47.1)              | 12 (40)                | 25 (49)               | 53 (48.2)                 |
| Biliary tract          | 24 (12.5)              | 3 (10)                 | 5 (9.8)               | 16 (14.5)                 |
| Others<sup>d</sup>     | 77 (40.3)              | 15 (50)                | 21 (41.2)             | 41 (37.3)                 |

<sup>a</sup>P value for B2 vs A/B1 = 0.03.
<sup>b</sup>P value for B2 vs D = 0.09.
<sup>c</sup>P value for D vs A/B1 = 0.07.
All other comparisons, P value $\geq 0.1$.
<sup>d</sup>Other sources were: unknown, 25 patients; intraabdominal (non-biliar), 24; respiratory tract, 10; catheter-related, 9; miscellaneous, 8.
Data are expressed as number of cases (%) except where specified.
doi:10.1371/journal.pone.0044238.t002
BSI; C4 (mostly B2 and ST131, CTX-M-15 producers) with non-
urinary or biliary tract sources; and C5 (mostly D and CTX-M-14
producers) with BSI in non-predisposed patients. All these clusters
had moderate to high virulence scores. The classification of isolates
into clusters according to VF had been previously carried out by
Johnson et al. according to clonal groups [36]; however, we
constructed the clusters by considering exclusively the VF content
of the isolates and without taking into account neither the
phylogroups nor any other clonal relationship among isolates
because our aim was to specifically investigate the influence of FV

**Figure 1. Distribution of virulence factors according to clusters.** Percentage of isolates: white: 0–25%; pale grey, 26–50%; dark grey, 51–75%;
black, >75%. doi:10.1371/journal.pone.0044238.g001
content by itself in the epidemiology of the infections. Hypothetical implications from our data are that vaccines developed against specific VFs might not be efficacious in avoiding invasive infections due to ESBLEC in predisposed patients, and that reducing the antibiotic pressure in such patients might be a more important measure to try and reduce such infections in these patients.

Strengths of our study include its multicenter nature, clinical data are comprehensive and were prospectively collected, and isolates are well characterized. However, it has some limitations: we could not compare the ESBLEC profiles with a control group of non-ESBL producers and thus used collections from other studies as a reference; we studied the genes codifying for VF, but

### Table 3. Phylogroups, virulence score, ESBLs, selected antimicrobial resistance, and associated patients' features of ESBL-producing E. coli isolates causing BSI according to virulence profile clusters.

| Phylogroups | Cluster C1 (n = 55) | Cluster C2 (n = 11) | Cluster C3 (n = 8) | Cluster C4 (n = 22) | Cluster C5 (n = 25) | Cluster C6 (n = 7) | Other isolates (n = 63) |
|-------------|---------------------|---------------------|-------------------|---------------------|---------------------|---------------------|------------------------|
| Phylogroups |                     |                     |                   |                     |                     |                     |                        |
| B2          | 0*                  | 0*                  | 25                | 90.9*               | 0*                  | 57.1                | 6.3                    |
| D           | 10.9                | 54.4                | 75*               | 9.1                 | 72*                 | 42.9                | 15.9                   |
| A           | 23.6                | 18.2                | 0*                | 0*                  | 16                  | 0*                  | 57.1                   |
| B1          | 65.5*               | 27.3                | 0*                | 0*                  | 12                  | 0*                  | 20.6                   |

Virulence score, median (IQR) 5 (5–6) * 8 (7–9)* 6 (6–7) 10 (10–12)* 8 (8–9)* 14 (12–15)* 4 (2–5)

ESBL groups

- **CTX-M-1 group**: 16.4 18.2 50 68.2* 8 28.6 12.7
- **CTX-M-9 group**: 70.9 72.7 62.5 27.3* 84 57.1 61.9
- **SHV group**: 16.4 9.1 0 4.5 16 14.3 27

Antimicrobial resistance

- **Ciprofloxacin**: 72.7 45.5 50 81.8 64 28.6* 69.8
- **Amoxicillin-clavulanic acid**: 29.1 45.5 37.5 68.2* 32 57.1 34.0
- **Tobramycin**: 7.3 18.2 12.5 54.5* 0* 14.3 22.2

Patients' features

- **Age in years, median (IQR)**: 68 (50–76) * 73 (66–78) 76 (70–83) 72 (57–79) 71 (52–77) 80 (58–84) 70 (58–80)
- **Male gender**: 58.2 54.5 50 63.6 48 42.9 57.1
- **Community-onset**: 50.9 45.5 62.5 50 56 28.6 47.6
- **Nursing home resident**: 1.8 9.1 12.5 13.6 12 0 4.8
- **Median Charlson index (IQR)**: 2 (2–5) 2 (1–5) 2 (1–4) 2 (2–4) 3 (2–4) 3 (1–3) 2 (1–4)
- **Predisposing factor, local**: 72.7 72.7 75 59.1 44* 85.7 60.3
- **Predisposing factor, systemic**: 60 37.3 50 50 50 40 71.4 54
- **Urinary tract source**: 52.7 81.8* 37.5 40.9 48 28.6 41.3
- **Biliary tract source**: 7.3 0 25 0 12 28.6 20.6
- **Other sources**: 40 18.2 37.5 59.1* 40 42.9 38.1

### Table 4. Multivariate analysis of variables associated with specific sources of bloodstream infection.

| OR (95% CI) P |
|---------------|
| Urinary tract source |
| Age (per year) | 1.02 (1.00–1.04) 0.009 |
| Local predisposing factor | 2.10 (1.11–3.98) 0.002 |
| Systemic predisposing factor | 0.57 (0.31–1.04) 0.07 |
| Cluster C2 | 5.05 (0.96–26.48) 0.05 |

| Non urinary or biliary tract sources |
| Age (per year) | 0.96 (0.94–0.98) 0.001 |
| Local predisposing factor | 0.27 (0.14–0.54) <0.001 |
| Systemic predisposing factor | 2.75 (1.41–5.36) 0.003 |
| Cluster C4 | 2.89 (1.05–7.93) 0.03 |

### Table 5. Multivariate analysis of variables associated with absence of local or systemic predisposing conditions.

| OR (95% CI) P |
|---------------|
| Absence of systemic and local predisposing factors |
| Age (per year) | 0.97 (0.94–1.00) 0.04 |
| Community-onset BSI | 2.62 (1.02–6.76) 0.04 |
| No previous antibiotics | 5.69 (2.24–14.45) <0.001 |
| Cluster 5 | 2.80 (0.99–7.93) 0.05 |

*P values <0.05 in comparison with isolates not included in the cluster.

Data are presented as percentage of isolates in each cluster except where specified.

doi:10.1371/journal.pone.0044238.t003

doi:10.1371/journal.pone.0044238.t004

doi:10.1371/journal.pone.0044238.t005
Acknowledgments

Other participants from the ESBL-REIP/GEIH group are: Paloma Gióon (Hospital Universitario Gregorio Marañón, Madrid, Spain), José Ramón Hernández (Hospital Universitario Virgen Macarena, Sevilla, Spain), Jose M. Cincer (Hospital Universitario Virgen del Rocio, Sevilla, Spain), Carmen Peña (Hospital Universitario de Bellvitge, Barcelona, Spain), Manuel Almela (Hospital Clinic, Barcelona, Spain), Benito Almirante (Hospital Universitario Vall d’Hebrón, Barcelona, Spain), Fabio Gril (Hospital Universitario Ramón y Cajal, Madrid; present address, Hospital Universitario La Paz, Madrid, Spain), Javier Colomina (Hospital de la Ribera, Alzira, Valencia, Spain), Monserrat Giménez (Hospital Germans Trias i Pujol, Badalona, Spain), Antonio Oliver (Hospital Son Espases, Palma de Mallorca, Spain), Juan Pablo Horcajada (Hospital Universitario Marqués de Valdecilla, Santander; present address, Hospital del Mar, Barcelona, Spain), Gemma Navarro (Corporacion Sanitaria Parc Taulí, Sabadell, Spain), Ana Coloma (Hospital Santa Creu i Sant Pau, Barcelona, Spain).

References

1. Picard B, Sevali J, Gourati S, Duriez P, Brahimi N, et al. (1999) The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect Immun 67: 546–553.
2. Johnson JR, Stell AL (2000) Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 181: 261–272.
3. Sprent MR, Kuskowski MA, Owens K, Gajewski A, Johnson JR (2004) Virulence factor profiles and phylogenetic background of Escherichia coli isolates identified according to their virulence profile were expected; neither PGs or specific VF were consistently associated with predisposing features or sources of BSI; and some clusters of isolates identified according to their virulence profile were identified and associated with specific source or acquisition of BSI in the absence of predisposing factors.
4. Moreno E, Planells I, Prats G, Planes AM, Prates T, et al. (2006) In conclusion, bacteremic ESBL-EC more frequently belonged to phylogeny and virulence in Escherichia coli isolates: group A and B1 causing extraintestinal infection. Emer infect Microbiol Clin 24: 403–409.
5. Johnson JR, Russo TA (2005) Molecular epidemiology of extraintestinal pathogenic (uropathogenic) Escherichia coli. Int J Med Microbiol 295: 383–404.
6. Wang MC, Tseng CC, Chen CY, Wu JH, Huang JJ (2002) The role of bacterial virulence and host factors in patients with Escherichia coli bacteremia who have acute cholangitis or upper urinary tract infection. Clin Infect Dis 35: 1161–1166.
7. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruiz M, et al. (2010) Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50: 40–46.
8. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Cisneros JM, et al. (2010) Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Clin Microbiol 48: 1726–1731.
9. van Boeckel TP, Peirano G, Goossens WH, van der Vorm ER, Van Westenoom M, et al. (2011) Clinical and molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob Agents Chemother 55: 3576–3578.
10. Lavigne JP, Blanc‐Potard AB, Bourg G, Morreau J, Chanal C, et al. (2006) Virulence genotype and hematologic‐killing properties of extra‐intestinal Escherichia coli isolating causing CTX‐M β‐lactamases. Clin Microbiol Infect 12: 1199–1206.
11. Clermont O, Lavallay M, Vimont S, Deschamps C, Forestier E, et al. (2008) The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogeny subgroup. J Antimicrob Chemother 63: 1024–1029.
12. Lavigne JP, Vergunst AC, Gorlet I, Soto A, Combescur E, et al. (2012) Virulence potential and genomic mapping of the worldwide clone Escherichia coli O25b-ST131. PLoS One 7: e34238.
13. Charbon ME, Pompey P, Alex KL, MacKenzie CR (1987) A new method of classifying prostatic co-morbidity in longitudinal studies: development and validation. J Chron Dis 40: 373–383.
14. Clinical and Laboratory Standard Institute (CLSI) (2009) Performance Standards for Antimicrobial Susceptibility Testing; 19th Informational Supplement. CLSI document M100-S19. CLSI, Wayne, PA, USA.
15. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, et al. (2009) Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 64: 274–277.
16. Clermont O, Bonacorsi S, Bingen E (2000) Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 66: 4555–4558.
17. Le Bourgogne C, Archambaud M, Labigne A (1992) Rapid and specific detection of the pap, afa, and etc. adhesion-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J Clin Microbiol 30: 1189–1193.
18. Karkkainen UM, Kauppinen J, Ikaheimo R, Katila ML, Siitonen A (1998) Rapid and specific detection of three different G adhesin classes of P-fimbriae in uropathogenic Escherichia coli by polymerase chain reaction. J Microbiol Methods 34: 23–29.
19. Nakano M, Yamamoto S, Terai A, Ogawa O, Makino SI, et al. (2001) Structural and sequence diversity of the pathogenicity island of uropathogenic Escherichia coli which encodes the USP protein. FEMS Microbiol Lett 205: 71–76.
20. Russo TA, Carlino UB, Johnson JR (2001) Identification of a new iron-regulated virulence gene, iut, in an extraintestinal pathogenic isolate of Escherichia coli. Infect Immun 69: 6209–6216.
21. Girardeau JP, Lavollay M, Deschamps C, Forestier C, Forestier E, et al. (2008) Intracranial emergence of clone ST131 as a cause of community-acquired infections. Emer infect Microbiol Clin 24: 403–409.
22. Clermont O, Bonacorsi S, Bingen E (2000) Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 66: 4555–4558.
23. Le Bourgogne C, Archambaud M, Labigne A (1992) Rapid and specific detection of the pap, afa, and etc. adhesion-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J Clin Microbiol 30: 1189–1193.
24. Nakano M, Yamamoto S, Terai A, Ogawa O, Makino SI, et al. (2001) Structural and sequence diversity of the pathogenicity island of uropathogenic Escherichia coli which encodes the USP protein. FEMS Microbiol Lett 205: 71–76.
25. Blanco M, Blanco JE, Alonso MP, Mora A, Balsalobre C, et al. (1997) Detection of pap, afa and etc. adhesion-encoding operons in uropathogenic Escherichia coli strains: relationship with expression of adhesins and production of toxins. Rev Microbiol 148: 745–755.
26. Yamamoto S, Kuri H, Kurazono H, Takeda Y, et al. (1995) Detection of virulence factors in Escherichia coli by multiplex polymerase chain reaction. FEMS Immunol Med Microbiol 12: 85–90.
27. Cisneros JM, Amano T (2004) Serogroups and virulence genotypes of Escherichia coli isolated from patients with sepsis. Braz J Med Biol Res 37: 887-883.
28. Nakano M, Yamamoto S, Terai A, Ogawa O, Makino SI, et al. (2001) Structural and sequence diversity of the pathogenicity island of uropathogenic Escherichia coli which encodes the USP protein. FEMS Microbiol Lett 205: 71–76.
29. Russo TA, Carlino UB, Johnson JR (2001) Identification of a new iron-regulated virulence gene, iut, in an extraintestinal pathogenic isolate of Escherichia coli. Infect Immun 69: 6209–6216.
30. Girardeau JP, Lalouet L, Saill AI, De Champs C, Le Bourgogne C (2003) Extended virulence genotype of pathogenic Escherichia coli isolates carrying the afa- or etc. adhesion-encoding operon. Appl Environ Microbiol 72: 2373–2377.
31. Nicolas-Chanoine MH, Blanco J, LeFou-Quibault V, Demarty R, Alonso MP, et al. (2008) Intercontinental emergence of Escherichia coli clone O25b-H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61: 271–281.
32. Pitout JDD, Gregson DG, Campbell L, Laupland KB (2009) Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 53: 1086–2051.
33. Brisse S, Dianecourt L, Laueruma C, Vigan M, Caro V, et al. (2012) Phylogenetic distribution of CTX-M and non-ESBL producing Escherichia coli isolates: group
B2 isolates, except clone ST131, rarely produce CTX-M enzymes. J Clin Microbiol (in press).

35. Bert F, Johnson JR, Ouaattara B, Leflon-Guibout V, Johnston B, et al (2010) Genetic diversity and virulence profiles of *Escherichia coli* isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J Clin Microbiol 48: 2709-2714.

36. Johnson JR, O’Bryan TT, Kusakowski M, Maslow JN (2001) Ongoing horizontal and vertical transmission of virulence genes and *papA* alleles among *Escherichia coli* blood isolates from patients with diverse source bacteremia. Infect Immun 69: 5363-5374.